Compare Religare Enterprises with Indoco Remedies - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

RELIGARE ENT vs INDOCO REMEDIES - Comparison Results

RELIGARE ENT     Change

Promoted by Mr. Malvinder Mohan Singh and Mr. Shivinder Mohan Singh , Religare Enterprises is a financial services company, offering a wide range of financial products and services targeted at retail investors, high net worth individuals and corporat... More

INDOCO REMEDIES 
   Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    RELIGARE ENT INDOCO REMEDIES RELIGARE ENT/
INDOCO REMEDIES
 
P/E (TTM) x -12.4 82.4 - View Chart
P/BV x 1.0 4.8 20.8% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 RELIGARE ENT   INDOCO REMEDIES
EQUITY SHARE DATA
    RELIGARE ENT
Mar-18
INDOCO REMEDIES
Mar-18
RELIGARE ENT/
INDOCO REMEDIES
5-Yr Chart
Click to enlarge
High Rs238317 74.9%   
Low Rs34178 19.3%   
Sales per share (Unadj.) Rs126.2113.1 111.6%  
Earnings per share (Unadj.) Rs-58.24.5 -1,302.7%  
Cash flow per share (Unadj.) Rs-56.311.8 -477.0%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs82.273.2 112.2%  
Shares outstanding (eoy) m204.9592.15 222.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.12.2 49.2%   
Avg P/E ratio x-2.355.5 -4.2%  
P/CF ratio (eoy) x-2.421.0 -11.5%  
Price / Book Value ratio x1.73.4 48.9%  
Dividend payout %022.4 0.0%   
Avg Mkt Cap Rs m27,86322,830 122.0%   
No. of employees `000NA5.5 0.6%   
Total wages/salary Rs m4,9842,209 225.6%   
Avg. sales/employee Rs Th760,811.81,910.1 39,831.7%   
Avg. wages/employee Rs Th146,573.5405.0 36,193.9%   
Avg. net profit/employee Rs Th-350,735.375.5 -464,835.0%   
INCOME DATA
Net Sales Rs m25,86810,419 248.3%  
Other income Rs m1,06447 2,268.4%   
Total revenues Rs m26,93210,466 257.3%   
Gross profit Rs m-3,8561,349 -285.8%  
Depreciation Rs m376677 55.5%   
Interest Rs m12,610235 5,363.8%   
Profit before tax Rs m-15,779484 -3,260.0%   
Minority Interest Rs m1,5790-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2,27472 -3,141.3%   
Profit after tax Rs m-11,925412 -2,897.2%  
Gross profit margin %-14.912.9 -115.1%  
Effective tax rate %14.415.0 96.4%   
Net profit margin %-46.14.0 -1,167.0%  
BALANCE SHEET DATA
Current assets Rs m76,1605,373 1,417.5%   
Current liabilities Rs m72,7514,157 1,750.1%   
Net working cap to sales %13.211.7 112.9%  
Current ratio x1.01.3 81.0%  
Inventory Days Days068 0.0%  
Debtors Days Days4073 55.2%  
Net fixed assets Rs m15,0416,244 240.9%   
Share capital Rs m2,050184 1,112.1%   
"Free" reserves Rs m14,7976,566 225.4%   
Net worth Rs m16,8466,750 249.6%   
Long term debt Rs m58,2871,233 4,728.0%   
Total assets Rs m158,76212,363 1,284.2%  
Interest coverage x-0.33.1 -8.2%   
Debt to equity ratio x3.50.2 1,894.4%  
Sales to assets ratio x0.20.8 19.3%   
Return on assets %0.45.2 8.3%  
Return on equity %-70.86.1 -1,160.8%  
Return on capital %-2.19.0 -23.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m03,762 0.0%   
Fx outflow Rs m121,143 1.1%   
Net fx Rs m-122,619 -0.5%   
CASH FLOW
From Operations Rs m57,2271,227 4,663.2%  
From Investments Rs m-4,220-1,360 310.3%  
From Financial Activity Rs m-63,772-388 16,448.9%  
Net Cashflow Rs m-10,769-521 2,068.6%  

Share Holding

Indian Promoters % 50.9 59.2 86.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.9 12.5 7.2%  
FIIs % 15.3 6.0 255.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 32.9 22.4 146.9%  
Shareholders   26,518 12,805 207.1%  
Pledged promoter(s) holding % 68.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare RELIGARE ENT With:   CHOLAMANDALAM INVEST  NESCO  REPCO HOME  COMPACT DISC  TATA INVESTMENT  



Today's Market

SGX Nifty Up 169 Points, Why Stock Markets Surged Yesterday, First Tranche of SGBs 2021-22, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday amid steady fall in Covid-19 cases in India. The BSE Sensex gained over 850 points and Nifty crossed 14,900 in intraday trade.

Related Views on News

Indian Railway Finance Corporation IPO: Should You Apply? (IPO)

Jan 18, 2021

Monopolistic railway financer with impeccable asset quality.

CAMS IPO: Should You Apply? (IPO)

Sep 18, 2020

Does the company having 70% market share of the mutual fund registrar business have sound prospects?

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

RELIGARE ENT SHARE PRICE


May 18, 2021 09:35 AM

TRACK RELIGARE ENT

  • Track your investment in RELIGARE ENT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

RELIGARE ENT 8-QTR ANALYSIS

COMPARE RELIGARE ENT WITH

MARKET STATS